A controlled trial of rasagiline in early
Parkinson disease: the TEMPO Study
by
Parkinson Study Group.
Arch Neurol. 2002 Dec;59(12):1937-43

ABSTRACT

CONTEXT: Monotherapy with rasagiline mesylate may be useful in early Parkinson disease (PD). OBJECTIVE: To evaluate the safety and efficacy of the selective monoamine oxidase type B inhibitor rasagiline. DESIGN: Multicenter, 26-week, parallel-group, randomized, double-blind, placebo-controlled clinical trial. SETTING: Academically based movement disorders clinics. PATIENTS: Patients with early PD not requiring dopaminergic therapy (n = 404). INTERVENTION: Research participants were randomized to rasagiline mesylate at dosages of 1 mg or 2 mg per day or matching placebo. A 1-week escalation period was followed by a 25-week maintenance period. MAIN OUTCOME MEASURE: The primary prespecified measure of efficacy was the change in the total Unified Parkinson's Disease Rating Scal score between baseline and 26 weeks of treatment, comparing each active treatment group with the placebo group. RESULTS: Monotherapy with rasagiline was effective in this 26-week study. The adjusted effect size for the total Unified Parkinson's Disease Rating Scale was -4.20 units comparing 1 mg of rasagiline and placebo (95% confidence interval, -5.66 to -2.73 units; P<.001) and -3.56 units comparing a 2-mg dosage and placebo (95% confidence interval, -5.04 to -2.08 units; P<.001). There were no meaningful differences in the frequency of adverse events or premature withdrawals among the treatment groups. CONCLUSIONS: Rasagiline is effective as monotherapy for patients with early PD. The 2 dosages in this trial were both effective relative to placebo. Further study is warranted to evaluate the longer-term effects of rasagiline in PD.

MAOIs
Levodopa
Rasagiline
Neuroprotection
Parkinson's disease
Rasagiline: structure
MAO-b inhibitors/PD
Anti-apoptotic activity
Molecular mechanisms
Rasagiline monotherapy
Parkinson's disease: resources
Rasagiline and the mitochondria
Antioxidant strategies against aging
New drugs to treat Parkinson's disease
Rasagiline versus selegiline metabolites
Dual AChE and MAO inhibitors and Alzheimer's
Rasagiline v selegiline: neuronal survival effects

Refs
HOME
HedWeb
Selegiline.com
BLTC Research
Nootropics.com
The Good Drug Guide
Paradise-Engineering
Supercentenarians.com
The Hedonistic Imperative
MDMA: Utopian Pharmacology